142 related articles for article (PubMed ID: 23998120)
1. VEGF and bFGF gene polymorphisms in patients with non-Hodgkin's lymphoma.
Wróbel T; Mazur G; Dzietczenia J; Gębura K; Kuliczkowski K; Bogunia-Kubik K
Biomed Res Int; 2013; 2013():159813. PubMed ID: 23998120
[TBL] [Abstract][Full Text] [Related]
2.
Wróbel T; Butrym A; Łacina P; Rybka J; Gębura K; Mazur G; Bogunia-Kubik K
Anticancer Res; 2017 Apr; 37(4):1799-1803. PubMed ID: 28373444
[TBL] [Abstract][Full Text] [Related]
3. Association of VEGF genetic polymorphisms with the clinical characteristics of non-Hodgkin's lymphoma.
Diao LP; Yu XM; Gao YH; Li Y; Liu HS; Liu LH; Zhou RM; Wang N; Wu LL; Wang SJ
J Cancer Res Clin Oncol; 2009 Nov; 135(11):1473-81. PubMed ID: 19649652
[TBL] [Abstract][Full Text] [Related]
4. VEGF and bFGF gene polymorphisms in Polish patients with B-CLL.
Wróbel T; Mazur G; Dzietczenia J; Gebura K; Kuliczkowski K; Bogunia-Kubik K
Med Oncol; 2013 Mar; 30(1):456. PubMed ID: 23335070
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients.
Salven P; Orpana A; Teerenhovi L; Joensuu H
Blood; 2000 Dec; 96(12):3712-8. PubMed ID: 11090051
[TBL] [Abstract][Full Text] [Related]
6. The Relationships between Polymorphisms in Genes Encoding the Growth Factors TGF-β1, PDGFB, EGF, bFGF and VEGF-A and the Restenosis Process in Patients with Stable Coronary Artery Disease Treated with Bare Metal Stent.
Osadnik T; Strzelczyk JK; Reguła R; Bujak K; Fronczek M; Gonera M; Gawlita M; Wasilewski J; Lekston A; Kurek A; Gierlotka M; Trzeciak P; Hawranek M; Ostrowska Z; Wiczkowski A; Poloński L; Gąsior M
PLoS One; 2016; 11(3):e0150500. PubMed ID: 26930482
[TBL] [Abstract][Full Text] [Related]
7. Angiogenic and coagulation-fibrinolysis factors in non Hodgkin's lymphoma.
Wróbel T; Poreba M; Mazur G; Poreba R; Pyszel A; Beck B; Steinmetz-Beck A; Andrzejak R; Kuliczkowski K
Neoplasma; 2006; 53(3):253-8. PubMed ID: 16652197
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non-Hodgkin's lymphoma.
Hazar B; Paydas S; Zorludemir S; Sahin B; Tuncer I
Leuk Lymphoma; 2003 Dec; 44(12):2089-93. PubMed ID: 14959852
[TBL] [Abstract][Full Text] [Related]
9. Correlations of EGF G1380A, bFGF C754G and VEGF T460C polymorphisms with malignant melanoma susceptibility and prognosis: A case-control study.
Wang XH; Long ZW
Gene; 2017 Jun; 617():44-53. PubMed ID: 28219779
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma.
Niitsu N; Okamato M; Nakamine H; Yoshino T; Tamaru J; Nakamura S; Higashihara M; Hirano M
Eur J Haematol; 2002 Feb; 68(2):91-100. PubMed ID: 12038454
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical expression of basic fibroblast growth factor, vascular endothelial growth factor, and their receptors in stage IV non-Hodgkin lymphoma.
Ho CL; Sheu LF; Li CY
Appl Immunohistochem Mol Morphol; 2002 Dec; 10(4):316-21. PubMed ID: 12607599
[TBL] [Abstract][Full Text] [Related]
12. VEGF overexpression is a valuable prognostic factor for non-Hodgkin's lymphoma evidence from a systemic meta-analysis.
Yang J; Li W; He X; Zhang G; Yue L; Chai Y
Dis Markers; 2015; 2015():786790. PubMed ID: 25810565
[TBL] [Abstract][Full Text] [Related]
13. A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma.
Salven P; Teerenhovi L; Joensuu H
Blood; 1999 Nov; 94(10):3334-9. PubMed ID: 10552942
[TBL] [Abstract][Full Text] [Related]
14. The prognostic significance of VEGF-C and VEGF-A in non-Hodgkin lymphomas.
Paydas S; Seydaoglu G; Ergin M; Erdogan S; Yavuz S
Leuk Lymphoma; 2009 Mar; 50(3):366-73. PubMed ID: 19347725
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of serum proangiogenic molecules in patients with de novo non-Hodgkin lymphomas.
Rujirojindakul P; Lekhakula A
ScientificWorldJournal; 2012; 2012():215231. PubMed ID: 22629121
[TBL] [Abstract][Full Text] [Related]
16. Angiogenesis and mast cells in non-Hodgkin's lymphoma: a strong correlation in angioimmunoblastic T-cell lymphoma.
Fukushima N; Satoh T; Sano M; Tokunaga O
Leuk Lymphoma; 2001 Aug; 42(4):709-20. PubMed ID: 11697501
[TBL] [Abstract][Full Text] [Related]
17. [Vascular endothelial growth factor (VEGF) serum concentration in non-Hodgkin's lymphoma patients].
Wróbel T; Mazur G; Usnarska-Zubkiewicz L; Kuliczkowski K
Pol Arch Med Wewn; 2004 Aug; 112(2):919-23. PubMed ID: 15675266
[TBL] [Abstract][Full Text] [Related]
18. Common single nucleotide polymorphisms in the vascular endothelial growth factor gene and colorectal cancer risk.
Hofmann G; Langsenlehner U; Renner W; Langsenlehner T; Yazdani-Biuki B; Clar H; Gerger A; Wehrschuetz M; Samonigg H; Krippl P
J Cancer Res Clin Oncol; 2008 May; 134(5):591-5. PubMed ID: 17938959
[TBL] [Abstract][Full Text] [Related]
19. Gastric cancer risk predisposition and prognostic significance of vascular endothelial growth factor (VEGF) gene polymorphisms--a case-control study in an Omani population.
Al-Moundhri MS; Al-Nabhani M; Burney IA; Al-Farsi AA; Al-Bahrani B
Mol Carcinog; 2009 Dec; 48(12):1170-6. PubMed ID: 19676106
[TBL] [Abstract][Full Text] [Related]
20. Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma.
Giles FJ; Vose JM; Do KA; Johnson MM; Manshouri T; Bociek G; Bierman PJ; O'Brien SM; Kantarjian HM; Armitage JO; Albitar M
Leuk Res; 2004 Jun; 28(6):595-604. PubMed ID: 15120936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
